

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**BIOMED**  
**和鉑醫藥控股有限公司**  
**HBM Holdings Limited**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 02142)**

**INSIDE INFORMATION**  
**FURTHER BUSINESS UPDATE ON COLLABORATION WITH**  
**KELUN-BIOTECH IN CONNECTION WITH**  
**ANTIBODY-DRUG CONJUGATE**

This announcement is made by HBM Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd (“**Nona Biosciences**”), a wholly-owned subsidiary of the Company, has entered into two supplemental agreements (“**Supplemental Agreements**”) with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“**Kelun-Biotech**”), in which Nona Biosciences and Kelun-Biotech agreed that Kelun-Biotech is entitled to license two ADC products (product 1 and product 2) jointly developed by the two parties to a licensed third party. The Supplemental Agreement shall take effect upon the agreement between Kelun-Biotech and the third party taking effect.

Pursuant to the Supplemental Agreements, Nona Biosciences is entitled to receive 30% of the proceeds derived from the two products (product 1 and product 2), including:

Product 1

- Product 1 is a project that Nona Biosciences license Kelun-Biotech to authorize to a third party, and Nona Biosciences is entitled to receive 30% of the upfront payment, milestone payments and tiered royalties of product 1;
- The upfront payment of product 1 is US\$30 million, and Nona Biosciences is entitled to receive 30% of such payment.

Product 2

- Product 2 is a project that Nona Biosciences license Kelun-Biotech to co-develop with a third party;
- Nona Biosciences is entitled to receive 30% of the upfront payment, milestone payments and tiered royalties of product 2.

The License Agreement (as supplemented by the Supplemental Agreement) between Kelun-Biotech and the Company is of a revenue nature in the ordinary and usual course of business of the Group and does not constitute notifiable transaction under Chapter 14 of the Listing Rules.

## **ABOUT NONA BIOSCIENCES**

Nona Biosciences, a wholly-owned subsidiary of the Company, is a global biotechnology company committed to providing a total solution from “Idea to IND” (“**I to I<sup>TM</sup>**”), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice<sup>®</sup> platforms and the experienced therapeutic antibody discovery team. Harbour Mice<sup>®</sup> generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice<sup>®</sup> and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs.

**Warning under Rule 18A.05 of the Listing Rules:** There is no assurance that any products as stated in this announcement will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

## **Forward-Looking Statements**

This announcement may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 23 December 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.*